MedTrace Logo

Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese Patients

NCT03093545 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-04-04

No results posted yet for this study

Summary

A single center, prospective cohort, open-label study of rabies post exposure program with equine rabies immunoglobulin (ERIG) and purified chick-embryo cell (PCEC) rabies vaccine in WHO category III exposed patients at Siriraj Hospital, Thailand aims to compare serum RVNA responses between obese (BMI \> 30 kg/m2) and normal weight/underweight (BMI \< 25 kg/m2) and to evaluate adverse events occurring after immunization on days 7, 14 and 28.

Conditions

  • Rabies

Interventions

BIOLOGICAL

Equine Rabies Immunoglobulin

40 IU per kg of body weight of ERIG at Day 0

BIOLOGICAL

Purified chick-embryo cell rabies vaccine

1 ml of PCEC Rabies vaccine on days 0, 3, 7, 14 and 28.

Sponsors & Collaborators

  • VINS Bioproducts Ltd.

    collaborator UNKNOWN

  • Biogentech Co.,LTD

    collaborator UNKNOWN

  • Mahidol University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-10-31
Completion
2016-11-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03093545 on ClinicalTrials.gov